Literature DB >> 1163890

Pulmonary melioidosis. Observations in thirty-nine cases.

E D Everett, R A Nelson.   

Abstract

During the 6-year period from 1965 through 1970, 39 patients with pulmonary melioidosis were treated at Fitzsimons Army Medical Center. Although this is a disease with a well-defined endemic area that does not include the United States, cases will no doubt continue to be seen in this country. These cases may result from acute infection in the endemic area, with subsequent travel to this country, or from delayed reactivation of a latent infection acquired months or years earlier. Given the potential for occurrence of this disease in the United States, continued awareness by the medical profession is important. The typical patient with subacute or chronic pulmonary melioidosis presents with fever, productive cough, weight loss, and a history of visiting an endemic area sometime in the past. Chest radiographs disclose upper lobe infiltrates and/or cavitation, suggesting granulomatous disease. With careful bacteriologic examination, sputum cultures are positive for Pseudomonas pseudomallei, which is susceptible to tetracycline, chloramphenicol, sulfonamides, and kanamycin. The titer of the indirect hemagglutinating antibodies will almost always be greater than 1:40. Most patients respond to therapy with tetracycline alone of in combination with chloramphenicol. Occasionally, a patient may require surgical intervention; if so, ideally the sputum should be negative, and a lobectomy, rather than segmentectomy, should be performed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1163890     DOI: 10.1164/arrd.1975.112.3.331

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  18 in total

Review 1.  Illnesses Associated with Freshwater Recreation During International Travel.

Authors:  Daniel L Bourque; Joseph M Vinetz
Journal:  Curr Infect Dis Rep       Date:  2018-05-22       Impact factor: 3.725

2.  An ELISA-disc procedure for antibodies toPseudomonas pseudomallei: application for a serological study of melioidosis in an endemic area.

Authors:  N Embi; D Devarajoo; R Mohamed; G Ismail
Journal:  World J Microbiol Biotechnol       Date:  1993-01       Impact factor: 3.312

3.  In vitro susceptibilities of Burkholderia mallei in comparison to those of other pathogenic Burkholderia spp.

Authors:  D J Kenny; P Russell; D Rogers; S M Eley; R W Titball
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 4.  Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature.

Authors:  Ella M Meumann; Allen C Cheng; Linda Ward; Bart J Currie
Journal:  Clin Infect Dis       Date:  2011-11-04       Impact factor: 9.079

5.  Pseudomonas pseudomallei infection from drowning: the first reported case in Taiwan.

Authors:  N Lee; J L Wu; C H Lee; W C Tsai
Journal:  J Clin Microbiol       Date:  1985-09       Impact factor: 5.948

6.  Melioidosis: an emerging infection in Taiwan?

Authors:  P R Hsueh; L J Teng; L N Lee; C J Yu; P C Yang; S W Ho; K T Luh
Journal:  Emerg Infect Dis       Date:  2001 May-Jun       Impact factor: 6.883

7.  Pathogenesis of percutaneous infection of goats with Burkholderia pseudomallei: clinical, pathologic, and immunological responses in chronic melioidosis.

Authors:  Carl Soffler; Angela M Bosco-Lauth; Tawfik A Aboellail; Angela J Marolf; Richard A Bowen
Journal:  Int J Exp Pathol       Date:  2014-02-27       Impact factor: 1.925

8.  Melioidosis with brain abscess.

Authors:  S Pit; F K Chea; F Jamal
Journal:  Postgrad Med J       Date:  1988-02       Impact factor: 2.401

9.  Activities of five new fluoroquinolones against Pseudomonas pseudomallei.

Authors:  M D Winton; E D Everett; S A Dolan
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

10.  Musculoskeletal melioidosis: clinical and imaging features.

Authors:  M H Pui; A P Tan
Journal:  Skeletal Radiol       Date:  1995-10       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.